èšåºæ®µéã®ãã€ãªå»è¬åäŒæ¥ã§ãã Actinium Pharmaceuticals, Inc. ã¯ã骚é«ç§»æ€ (BMT) ãŸãã¯çްèçæ³ã®äžçš®ãããã³ãã®ä»ã®é€å现èçæ³ã®æ²»çæ³ã®éçºãšåååã«æ³šåããŠããŸããå瀟ã®äž»å補ååè£ã§ãã I-131 ã¢ããã¹ã¿ãã (Iomab-B) ã¯ãBMT ã®æºåã®ããã®é«éœ¢è
ã®åçºãŸãã¯é£æ²»æ§æ¥æ§éªšé«æ§çœè¡ç
詊éšã®éèŠãªç¬¬ III çžèšåºè©Šéšäžã§ããããŸãã¡ã¢ãªã¢ã« ã¹ããŒã³ ã±ã¿ãªã³ã°çã»ã³ã¿ãŒãšå
±åã§ CD19 CAR T 现èçæ³ã®ç¬¬ I çžç ç©¶äžã§ããå瀟ã¯ãŸããæšçæ²»ççšæåCD45ããã³CD33ãæšçãšããèšåºæ®µéã®æäœæŸå°ç·è€åäœã®å€çŸæ£ã倿šçãã€ãã©ã€ã³ãéçºããŠãããæ¥æ§éªšé«æ§çœè¡ç
ã骚é«ç°åœ¢æçå矀ãå€çºæ§éªšé«è
«ãªã©ã®ããŸããŸãªè¡æ¶²æªæ§è
«çã®æ£è
ã«å¯Ÿããæ²»çè¬ãšããŠããŸãä»ã®æ²»çæ³ãšã®äœµçšãŸãã¯åç¬æ²»çè¬ãšããŠäœ¿çšãããŠããŸããActinium Pharmaceuticals, Inc.ã¯ãAstellas Pharma, Inc.ãšå
±åç ç©¶ãè¡ããå瀟ã®Antibody Warhead Enablingæè¡ãã©ãããã©ãŒã ã䜿çšããæšçæŸå°ç·çæ³ãéçºããŠããŸããå瀟ã¯2000幎ã«èšç«ããããã¥ãŒãšãŒã¯å·ãã¥ãŒãšãŒã¯ã«æ ç¹ã眮ããŠããŸãã